Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor

Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor

The development of neutralizing antibodies (inhibitors) against factor VIII (FVIII) is a major complication of hemophilia A treatment. The sole clinical therapy to restore FVIII tolerance in patients with inhibitors remains immune tolerance induction (ITI) which is expensive, difficult to administer...

Full description

Bibliographic Details
Main Authors: Maria T. Georgescu, Paul C. Moorehead, Tongyao Liu, Jennifer Dumont, David W. Scott, Christine Hough, David Lillicrap
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Immunology
Subjects:
hemophilia A—complications
drug therapy
anti-drug antibodies
factor VIII inhibitors
recombinant factor VIII Fc
FcγRIIB
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.00138/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.00138/full

Similar Items